Relapsing Rhodococcus equi infection in a heart transplant recipient successfully treated with long-term linezolid.
We report a heart transplant recipient with Rhodococcus equi and Cryptococcus neoformans infection. Despite an initially relapsing course and the acquisition of resistance in vivo, the patient responded to 5 months of linezolid and 6 months of fluconazole. This is the 1st R. equi infection to be cured with linezolid in a heart transplant recipient.
Muñoz
Patricia
P
Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, 28007 Madrid, Spain.
Palomo
Jesús
J
Guinea
Jesús
J
Yañez
Juan
J
Giannella
Maddalena
M
Bouza
Emilio
E
D000081:Acetamides / Q000627:therapeutic use*; D000193:Actinomycetales Infections / Q000188:drug therapy* / Q000382:microbiology*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003453:Cryptococcosis / Q000188:drug therapy / Q000382:microbiology; D003455:Cryptococcus neoformans / Q000187:drug effects / Q000302:isolation & purification; D024881:Drug Resistance, Bacterial; D015725:Fluconazole / Q000627:therapeutic use; D006331:Heart Diseases / Q000150:complications; D006801:Humans; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000627:therapeutic use*; D012008:Recurrence; D016929:Rhodococcus equi / Q000187:drug effects / Q000302:isolation & purification*; D014180:Transplantation; D016896:Treatment Outcome
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D015725:Fluconazole; D000069349:Linezolid